As acceptance of flexible trial designs continues to advance, many sponsors are increasingly exploring alternate methods for dose escalation to support identification of a maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in open-label Early Phase or First-in-Human studies. Bayesian dose escalation designs have also coincided with advances in oncology therapy development, such as immunotherapies and antibody drug conjugates. These more flexible methods are viewed as potentially more appropriate than those initially designed for chemotherapy drug development. In this webinar, experts discuss several important aspects of Bayesian dose escalation designs used in oncology trials.
Key Topics Covered in this Webinar:
- Common types of open-label adaptive dose escalation designs
- Comparisons with rule-based designs
- How to apply and use these designs in oncology therapy development
- How to determine which design is best suited for your trial